CAREs 2025: Supporting community-based solutions that improve access to medicines

not used title

Today, PhRMA announced the 2025 recipients of its CAREs grant program. The initiative provides funding for community-led projects that help streamline care and improve access to medicines across the United States.

The 2025 cohort includes six organizations working across 15 states. Each recipient brings a tailored approach to helping patients understand their treatment options, navigate complex systems and get the care they need. Whether through school-based training, bilingual workshops or neighborhood outreach, these efforts reflect the critical role that trusted community organizations play in helping individuals and families access health services.

Congratulations to our 2025 CAREs Grant Recipients!

Patient Navigation for Arizonans Impacted by Cancer
Cancer Support Community | Arizona
Through a bilingual patient navigation program, this project will provide personalized cancer support services and education on cost-saving strategies for individuals in rural communities. By meeting people where they are, the initiative aims to make information and treatment more accessible.

Pediatric Medication Education and Management
Cure 4 The Kids Foundation | Nevada
Pharmacists at Cure 4 The Kids will provide individualized support for children with cancer, sickle cell disease and rare conditions. The program includes one-on-one education, multilingual materials and pharmacy coordination to improve treatment understanding, reduce dosing errors and support families navigating complex care plans.

Detroit RxConnect: Bridging Medicine Access in Underserved Communities
The Detroit Association of Black Organizations (DABO) | Michigan
Through community ambassador training, neighborhood canvassing and digital outreach, this program will connect Detroit residents with reliable health care information and resources. The campaign is designed to raise awareness about available services and improve access to life-saving medicines.

Seizure First Aid and Recognition Training for Schools
Epilepsy Foundation New England | Maine and Massachusetts
This project will train approximately 10,000 school staff to recognize seizures and administer rescue medications, improving response times and safety for students with epilepsy.

Empowering Families through Health Insurance Literacy and Advocacy
Organization for Latino Health Advocacy (OLHA) | California
In Southern California, OLHA will deliver bilingual, culturally tailored health insurance literacy workshops in local boxing gyms. The initiative combines community outreach, adapted education materials and policy research to help participants better understand their prescription drug benefits and make informed decisions about their care.

Expanding Holistic Health Care and Pharmacy Access
Southern Christian Leadership Conference | Global Policy Initiative
This initiative will offer workshops, virtual webinars and culturally relevant toolkits to help individuals understand prescription affordability programs, digital health tools and available support services. Activities will take place in communities across nine states (AL, AR, DE, GA, MD, MS, NC, RI, VA) and Washington, D.C.

The CAREs grant program is part of PhRMA’s ongoing efforts to support organizations working on the ground to improve patient access to medicines and strengthen care delivery. Each of these projects reflects a tailored, community-based approach to addressing real-world challenges, ensuring individuals and families have the tools and support they need to manage their health.

Lori M. Reilly, Esq.

Lori M. Reilly is chief operating officer at PhRMA, providing executive level management, leadership and strategic direction for the organization. In this role, Reilly oversees PhRMA’s advocacy activities, including its federal, state and international government affairs and alliance development work. Reilly provides strategic leadership and works across PhRMA to develop and advocate for practical policy solutions that will lower costs for patients.

Reilly, named by the Washingtonian as one of the 250 most influential people in D.C., has a long record of working with members of Congress on a bipartisan basis and collaborating with stakeholders across the health care industry. Reilly is a frequent presenter on industry-related issues, including testifying before Congress on multiple occasions.

Reilly has over two decades of experience at PhRMA; prior to her current role, Reilly was the executive vice president of policy, research and membership at PhRMA, leading the development and implementation of legislative, regulatory and political strategies to advance policies that encourage patient access and medical innovation. She has also served as counsel at the U.S. House of Representatives Committee on Commerce and was Counsel to a member of the House Ways and Means Committee.

Reilly received a B.A. in political science from the University of Nebraska-Lincoln where she graduated with honors, and a J.D. from the University of Nebraska College of Law. She currently resides in Alexandria, Virginia with her husband and their four children.

Lori Reilly

https://x.com/lreilly71

https://www.linkedin.com/in/lorireillyphrma/

Chief Operating Officer

New study: HPV vaccination helps prevent cervical cancer deaths

July 21, 2026

America's cancer research progress is real and worth protecting

May 28, 2026

Ahead of ASCO: Cancer innovation is promising, but policy choices matter

May 26, 2026

Advancing patient care: A look at new medicines approved in 2025

January 30, 2026

New analysis finds 340B hospitals push patients toward costly care to boost profits

January 21, 2026

Price setting policies put cancer gains in jeopardy

January 16, 2026

Improved treatments continue to lead to declining cancer mortality rates in the U.S.

February 25, 2025

Guest Perspective: Prioritize Innovative Care

February 11, 2025

Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024

February 3, 2025

Post-approval R&D is critical for fighting cancer. The IRA makes it more difficult.

November 13, 2024

The importance of partnership: A conversation with Takeda

October 10, 2024

The future of oncology R&D lies in policymakers’ hands

July 8, 2024

Showcasing the promise of biopharma at ASCO 2024

June 28, 2024

Championing cancer equity: Our drive for healthier AANHPI communities

May 1, 2024

The impact of innovative medicines: A caregiver's perspective

March 26, 2024

PhRMA awards $250,000 to community-based projects to improve equitable cancer outcomes

February 9, 2024

Three things to know about antibody drug conjugates

February 2, 2024

The IRA’s pill penalty threatens the future of oncology R&D

November 16, 2023

New Report: 1,600 cancer treatments and vaccines in clinical development

November 9, 2023

R&D leaders to Biden Administration: Your policies are undermining the Cancer Moonshot

October 18, 2023

Watch: New video series spotlights advances in biopharmaceutical science

August 24, 2023

Between hope and despair: Improving cancer outcomes

July 11, 2023

New report shows high-impact R&D happens after cancer medicines are first approved

July 10, 2023

New report shows how the Inflation Reduction Act stifles innovation for small molecule medicines

June 22, 2023

ASCO 2023: Protecting our progress in the fight against cancer

June 15, 2023

Highlights from ASCO 2023

June 8, 2023

IRA Impacts: Cancer treatment research and development

March 23, 2023

State policymakers can protect American innovation and help Americans live longer, healthier lives

February 9, 2023

ICYMI: Cancer death rate continues to decline due to treatment advances

January 25, 2023

Novel medicines approved in 2022 offer increased treatment options for patients

January 23, 2023

Stories from the lab: Researchers discuss innovative treatments for cancers of the blood

December 1, 2022

ICYMI: PhRMA COO Lori Reilly Esq. speaks with Jacob Van Naarden about the future of cancer research

November 8, 2022

Protecting treatment advances for breast cancer

October 31, 2022

Key takeaways from ASCO's annual meeting

June 10, 2022

ICYMI: First pediatric patient to receive CAR-T cell therapy celebrates 10 years of being cancer-free

May 25, 2022

Report: More than 500 medicines in development to treat disorders of the blood

May 18, 2022

4 things to know about biopharmaceutical efforts to fight cancer

February 24, 2022

New data show continued decline in death rates for cancer patients related to treatment advances

January 20, 2022

Recognizing National Immunization Awareness Month

August 31, 2021

Action needed to preserve the six protected classes

February 3, 2021

ICYMI: Cancer death rate continues decline due to advances in treatment

January 19, 2021

Report: More than 1,300 medicines and vaccines in development to help fight cancer

December 15, 2020

Study finds biopharmaceutical innovation is responsible for 35% of the increase in life expectancy from 1990 to 2015

October 21, 2020

New report explores setbacks that bring future cancer success stories

July 16, 2020

Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic

June 24, 2020

Cancer medicines cost twice as much at hospitals, study finds

January 21, 2020

Saving kids and dogs from shared cancers

September 17, 2018

New analysis shows that more medicines worldwide are available to U.S. patients

June 5, 2018

New analysis shows that HTA organizations may frequently restrict access to cancer treatments

June 1, 2018

New report and resources put cancer in context, showing more than 1,100 medicines and vaccines in development

May 30, 2018

Spending on medicines grew less than one percent in 2017

April 19, 2018

Patients pay the price when hospitals mark up cancer medicines

April 5, 2018

A new era in cancer

November 1, 2017

PhRMA, member companies and NIH create public-private partnership for immuno-oncology

October 12, 2017

What they are saying: Study on cancer R&D costs is not an accurate representation of marketplace

September 12, 2017

Protect your health: Important disaster preparedness tips for Harvey and Irma

September 6, 2017

Medicare Monday: New report highlights progress in fighting cancer with new physician-administered medicines

June 12, 2017

More than 240 immuno-oncology treatments in development to fight cancer

June 1, 2017

Medicines have significantly increased chances of cancer survival around the globe

May 24, 2017

ICYMI: Report highlights overall decrease in cancer death rates

April 3, 2017

This is not a video game: New TV ad showcases the destruction of a cancer cell by immune system

February 5, 2017

The 20-year journey yielding a new weapon against cancer

January 10, 2017

Significant progress fighting cancer: Death rate has dropped 25 percent

January 9, 2017

Cancer